Neos Therapeutics (NASDAQ:NEOS) Trading 5.1% Higher

Neos Therapeutics Inc (NASDAQ:NEOS) traded up 5.1% during trading on Friday . The stock traded as high as $1.93 and last traded at $1.85, 303,953 shares were traded during mid-day trading. A decline of 21% from the average session volume of 384,034 shares. The stock had previously closed at $1.76.

Several research analysts have recently commented on the stock. Zacks Investment Research lowered shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. ValuEngine raised shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. BMO Capital Markets lowered their price objective on shares of Neos Therapeutics from $4.00 to $3.00 and set a “market perform” rating for the company in a research note on Monday. Finally, Cantor Fitzgerald decreased their price target on shares of Neos Therapeutics from $20.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, June 12th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Neos Therapeutics currently has an average rating of “Buy” and an average price target of $6.05.

The business’s 50 day moving average is $1.43 and its 200-day moving average is $1.92. The company has a debt-to-equity ratio of 41.70, a current ratio of 1.13 and a quick ratio of 1.27. The company has a market cap of $92.00 million, a PE ratio of -1.16 and a beta of 1.19.

Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. The firm had revenue of $15.64 million during the quarter, compared to analysts’ expectations of $16.70 million. As a group, sell-side analysts predict that Neos Therapeutics Inc will post -0.55 EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of NEOS. BlackRock Inc. lifted its stake in Neos Therapeutics by 28.8% in the fourth quarter. BlackRock Inc. now owns 2,733,411 shares of the company’s stock worth $4,510,000 after acquiring an additional 610,660 shares during the last quarter. Stonepine Capital Management LLC lifted its stake in Neos Therapeutics by 10.2% in the second quarter. Stonepine Capital Management LLC now owns 4,971,014 shares of the company’s stock worth $6,413,000 after acquiring an additional 459,510 shares during the last quarter. Northern Trust Corp lifted its stake in Neos Therapeutics by 71.9% in the fourth quarter. Northern Trust Corp now owns 514,618 shares of the company’s stock worth $849,000 after acquiring an additional 215,241 shares during the last quarter. Paloma Partners Management Co purchased a new position in Neos Therapeutics in the second quarter worth approximately $275,000. Finally, Alambic Investment Management L.P. lifted its stake in Neos Therapeutics by 1,710.7% in the second quarter. Alambic Investment Management L.P. now owns 219,090 shares of the company’s stock worth $283,000 after acquiring an additional 206,990 shares during the last quarter. Institutional investors own 54.88% of the company’s stock.

Neos Therapeutics Company Profile (NASDAQ:NEOS)

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Featured Story: Coverage Ratio

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.